Taysha gene therapies announces second patient dosed with tsha-102 in the reveal phase 1/2 adult trial for the treatment of rett syndrome

Available clinical data from the two adult patients dosed with tsha-102 in the first cohort (low dose) to be discussed during upcoming quarterly earnings call following independent data monitoring committee (idmc) review

TSHA Ratings Summary

TSHA Quant Ranking